

TADA3 RABBIT PAB

Cat.#: S218665

Product Name: Anti-TADA3 Rabbit Polyclonal Antibody

Synonyms: ADA3; NGG1; hADA3; STAF54; TADA3L

UNIPROT ID: O75528 (Gene Accession - BC009240)

Background: DNA-binding transcriptional activator proteins increase the rate of transcription by interacting with the transcriptional machinery bound to the basal promoter in conjunction with adaptor proteins, possibly by acetylation and destabilization of nucleosomes. The protein encoded by this gene is a transcriptional activator adaptor and a component of the histone acetyl transferase (HAT) coactivator complex which plays a crucial role in chromatin modulation and cell cycle progression. Along with the other components of the complex, this protein links transcriptional activators bound to specific promoters, to histone acetylation and the transcriptional machinery. The protein is also involved in the stabilization and activation of the p53 tumor suppressor protein that plays a role in the cellular response to DNA damage. Alternate splicing results in multiple transcript variants of this gene.

Immunogen: Fusion protein of human TADA3

Applications: ELISA, IHC

Recommended Dilutions: IHC: 25-100; ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human, Mouse, Rat


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Epigenetics and Nuclear Signaling

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 218665(TADA3 Antibody) at a dilution of 1/20(Nucleus and Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the fusion protein and then with 218665(Anti-TADA3 Antibody) at dilution 1/20.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
